Medii and Asahi Kasei Therapeutics Collaborate to Optimize Early Diagnosis and Treatment of DIC
Medii and Asahi Kasei Therapeutics will launch a collaboration on June 1 to optimize the early diagnosis and treatment of Disseminated Intravascular Coagulation (DIC). They will establish a specialized consultation window for DIC within Medii’s physician platform, 'Medii E-Consult', to improve clinical care quality.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 20:00
- 🔍 Collected: May 20, 2026 at 11:31
- 🤖 AI Analyzed: May 20, 2026 at 12:02 (30 min after Collected)
Medii, Inc. and Asahi Kasei Therapeutics Co., Ltd. announced that they will begin a collaborative effort on June 1 to promote early diagnosis and optimal treatment of Disseminated Intravascular Coagulation (DIC).
In this initiative, the companies will jointly conduct awareness activities, including the promotion of a case consultation window staffed by experts well-versed in DIC within Medii's specialized physician consultation service, 'Medii E-Consult,' and the distribution of DIC-related clinical content. This initiative aims to provide physicians nationwide with rapid access to expert knowledge, contributing to improved quality of care and treatment optimization in DIC.
■ Background
DIC is a life-threatening condition where the balance between blood clotting and dissolution is lost, potentially leading to multi-organ failure and massive hemorrhage. Triggered by underlying conditions such as infections, cancer, trauma, or obstetric complications, its causes and progression vary widely per patient. Consequently, treatment plans are not uniform and must be adjusted to dynamically changing conditions, making it one of the most challenging areas of medical practice.
Recognizing these challenges, the collaboration was established between Asahi Kasei Therapeutics, which has been involved in disease awareness, and Medii, which supports knowledge sharing among physicians.
By creating an environment where primary physicians can discuss cases with expert specialists online, this collaboration enables decision-making support regardless of regional or institutional infrastructure.
■ DIC Case Consultation Window
URL: https://x.medii.jp/8c4eab
*Note: Medii E-Consult is intended for information sharing between physicians and is not a medical device. This service is for physicians only, and free membership registration is required.
■ Neutrality and Independence
Responses to consultations are based on the independent medical perspective of each expert specialist and are not influenced by Medii or Asahi Kasei Therapeutics.
In this initiative, the companies will jointly conduct awareness activities, including the promotion of a case consultation window staffed by experts well-versed in DIC within Medii's specialized physician consultation service, 'Medii E-Consult,' and the distribution of DIC-related clinical content. This initiative aims to provide physicians nationwide with rapid access to expert knowledge, contributing to improved quality of care and treatment optimization in DIC.
■ Background
DIC is a life-threatening condition where the balance between blood clotting and dissolution is lost, potentially leading to multi-organ failure and massive hemorrhage. Triggered by underlying conditions such as infections, cancer, trauma, or obstetric complications, its causes and progression vary widely per patient. Consequently, treatment plans are not uniform and must be adjusted to dynamically changing conditions, making it one of the most challenging areas of medical practice.
Recognizing these challenges, the collaboration was established between Asahi Kasei Therapeutics, which has been involved in disease awareness, and Medii, which supports knowledge sharing among physicians.
By creating an environment where primary physicians can discuss cases with expert specialists online, this collaboration enables decision-making support regardless of regional or institutional infrastructure.
■ DIC Case Consultation Window
URL: https://x.medii.jp/8c4eab
*Note: Medii E-Consult is intended for information sharing between physicians and is not a medical device. This service is for physicians only, and free membership registration is required.
■ Neutrality and Independence
Responses to consultations are based on the independent medical perspective of each expert specialist and are not influenced by Medii or Asahi Kasei Therapeutics.
FAQ
What is the launch date of the collaboration between Medii and Asahi Kasei Therapeutics for DIC?
The collaboration between Medii and Asahi Kasei Therapeutics for DIC launches on June 1.
Which product platform by Medii will feature a specialized consultation window for DIC?
Medii's physician platform 'Medii E-Consult' will feature a specialized consultation window for DIC.
What medical condition are Medii and Asahi Kasei Therapeutics focusing on in their June 1 collaboration?
Medii and Asahi Kasei Therapeutics are focusing on Disseminated Intravascular Coagulation (DIC).
How does Asahi Kasei Therapeutics contribute to the Medii E-Consult platform starting June 1?
Asahi Kasei Therapeutics collaborates on establishing a DIC consultation window on Medii E-Consult.
What specific improvement do Medii and Asahi Kasei Therapeutics aim for in DIC care by June 1?
They aim to optimize early diagnosis and treatment of DIC by launching a specialized consultation.